国产成人高清亚洲综合,国产成人精品无码一区二区老年人

Selinexor trans-isomer

NMR下載 COA and HPLC MSDS下載
names：
O=C(NNC1=NC=CN=C1)/C=C/N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2
CAS號：
1421923-86-5
MDL Number：
MF(分子式)： C17H11F6N7O MW(分子量)： 443.31
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫存描述	數(shù)量	總計(jì) (￥)

大包裝詢價(jià) 提供各種包裝，敬請垂詢
收藏商品商品點(diǎn)評加入購物車立即購買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	O=C(NNC1=NC=CN=C1)/C=C/N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2
英文別名	KPT-330 E-isomer; KPT330 trans isomer; E-KPT 330; Selinexor E-isomer; Selinexor trans-isomer
CAS號	1421923-86-5
Inchi	InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1+
InchiKey	DEVSOMFAQLZNKR-DAFODLJHSA-N
分子式 Formula	C17H11F6N7O
分子量 Molecular Weight	443.31
溶解度Solubility
性狀	Solid powder
儲(chǔ)藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說明	Selinexor trans-isomer(CAS:1421923-86-5 ):僅限應(yīng)用于工業(yè)或者科學(xué)研究過程中非醫(yī)療目的，不應(yīng)用于人類或動(dòng)物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。
Introduction	Selinexor trans-isomer is a trans-isomer of Selinexor or KPT-330, which is a CRM1-selective inhibitor of nuclear export. It inhibits protein trafficking from the nucleus and induces cell cycle arrest and apoptosis in mesothelioma cells.
Application1
Application2
Application3

警示圖
危險(xiǎn)性	Warning
危險(xiǎn)性警示
安全聲明
安全防護(hù)
備注

[1]Ben-Barouch S, Kuruvilla J. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL). Expert Opin Investig Drugs. 2019 Dec 17. doi: 10.1080/13543784.2020.1706087. [Epub ahead of print] PubMed PMID: 31847605.

[2]Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al Hallak MN, Tesfaye A, Kim S, Shidham V, Ramzi M, Philip PA. Preclinical assessment with clinical validation of Selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2019 Dec 12. pii: clincanres.1728.2019. doi: 10.1158/1078-0432.CCR-19-1728. [Epub ahead of print] PubMed PMID: 31831564.

[3] Vergote IB, Lund B, Peen U, Umajuridze Z, Mau-Sorensen M, Kranich A, Van Nieuwenhuysen E, Haslund C, Nottrup T, Han SN, Concin N, Unger TJ, Chai Y, Au N, Rashal T, Joshi A, Crochiere M, Landesman Y, Shah J, Shacham S, Kauffman M, Mirza MR. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecol Oncol. 2019 Dec 7. pii: S0090-8258(19)31663-4. doi: 10.1016/j.ygyno.2019.11.012. [Epub ahead of print] PubMed PMID: 31822399.

[4] Peterson TJ, Orozco J, Buege M. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma. Ann Pharmacother. 2019 Dec

[5]1060028019892643. doi: 10.1177/1060028019892643. [Epub ahead of print] PubMed PMID: 31793336.

5: Abboud R, Chendamarai E, Rettig MP, Trinkaus KM, Riedell PA, Abboud CN, Ghobadi A, Pusic I, Stockerl-Goldstein K, Schroeder MA, Vij R, Westervelt P, DiPersio JF, Uy GL. Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. Haematologica. 2019 Nov 21. pii: haematol.2019.236810. doi: 10.3324/haematol.2019.236810. [Epub ahead of print] PubMed PMID: 31753931.

對不起，暫無產(chǎn)品評價(jià)！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開